Linda Chia-Hui Yu
Overview
Explore the profile of Linda Chia-Hui Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu L
Life Sci
. 2024 Oct;
358:123153.
PMID: 39454992
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered an unprecedented public health crisis known as the coronavirus disease 2019 (COVID-19) pandemic. Gastrointestinal (GI) symptoms develop in patients...
2.
Guo T, Kuo W, Tsai Y, Yu L, Huang C
Curr Dev Nutr
. 2024 Sep;
8(9):104431.
PMID: 39263224
Background: Superior mesenteric ischemia/reperfusion (I/R) causes barrier dysfunction and facilitates bacterial translocation (BT) in the small intestine, which can even lead to systemic sepsis. Our previous research showed that luminal...
3.
She M, Hsieh Y, Lin L, Tu C, Wu M, Hsin L, et al.
Histol Histopathol
. 2023 Dec;
39(7):903-919.
PMID: 38108436
Objectives: Aberrant serotonin (5-hydroxytryptamine, 5-HT) metabolism and neurite outgrowth were associated with abdominal pain in irritable bowel syndrome (IBS). We previously demonstrated that 5-HT receptor subtype 7 (5-HT₇) was involved...
4.
Chiu P, Chang C, Huang P, Lin Y, Lin C, Yang H, et al.
J Med Chem
. 2023 Jul;
66(14):9684-9696.
PMID: 37413981
Irinotecan (), a prodrug of SN38 () approved by the US Food and Drug Administration for treating colorectal cancer, lacks specificity and causes many side effects. To increase the selectivity...
5.
Pai Y, Li Y, Turner J, Yu L
J Crohns Colitis
. 2023 Apr;
17(9):1471-1488.
PMID: 37004200
Background: Factors that contribute to inflammatory bowel disease [IBD] pathogenesis include genetic polymorphisms, barrier loss, and microbial dysbiosis. A major knowledge gap exists in the origins of the colitogenic microbiome...
6.
Huang C, Pai Y, Yu L
Oncology
. 2022 Jul;
100(10):555-568.
PMID: 35850102
Background: Altered glucose metabolism is associated with chemoresistance in colorectal cancer (CRC). This study aimed to illustrate the molecular mechanisms of glucose-mediated chemoresistance against irinotecan, a topoisomerase I inhibitor, focusing...
7.
Chang W, Yang Y, She M, Tu C, Lee T, Wu M, et al.
Lab Invest
. 2022 May;
102(9):1023-1037.
PMID: 35585132
Irritable bowel syndrome (IBS) is characterized by visceral hypersensitivity (VH) associated with abnormal serotonin/5-hydroxytryptamine (5-HT) metabolism and neurotrophin-dependent mucosal neurite outgrowth. The underlying mechanisms of VH remain poorly understood. We...
8.
Yu L, Wei S, Li Y, Lin P, Chang X, Weng J, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Aug;
13(1):57-79.
PMID: 34418587
Background & Aims: Microbiota dysbiosis and mucosa-associated bacteria are involved in colorectal cancer progression. We hypothesize that an interaction between virulent pathobionts and epithelial defense promotes tumorigenesis. Methods: Chemical-induced CRC...
9.
Huang Y, Lee T, Pai Y, Lin B, Turner J, Yu L
Carcinogenesis
. 2021 May;
42(7):961-974.
PMID: 34000008
Myosin light chain kinase (MLCK) regulates actinomyosin contraction. Two splice variants of long MLCK are expressed in epithelial cells and divergently regulate gut barrier functions; reduced MLCK levels in human...
10.
Chang C, Chiu P, Yang H, Juang Y, Lai Y, Lin T, et al.
J Med Chem
. 2021 Apr;
64(8):4450-4461.
PMID: 33819035
Overexpression of glucose transporters (GLUTs) in colorectal cancer cells is associated with 5-fluorouracil (, 5-FU) resistance and poor clinical outcomes. We designed and synthesized a novel GLUT-targeting drug conjugate, triggered...